NEWS
Our Latest News
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
Private equity healthcare specialist ARCHIMED announces the sale of DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders.
ARCHIMED’s NAMSA consolidates leadership in Medical Device Clinical Research, buying Clinlogix
August
2,
2021
ARCHIMED buys Stragen Pharma, a leader in the development, registration and distribution of hard-to-make generic drugs
June
24,
2021
ARCHIMED’s Fytexia buys B Natural, the European leader in the extraction and refinement of compounds produced by bees
June
1,
2021
ARCHIMED’s Direct Healthcare Group buys United Care BV
March
24,
2021
ARCHIMED’s Direct Healthcare Group acquires Talley
March
3,
2021
368